Atropine augments cardiac contractility by inhibiting cAMP-specific phosphodiesterase type 4

Perera, Ruwan K.; Fischer, Thomas; Wagner, Michael; Dewenter, Matthias; Vettel, Christiane; Bork, Nadja I.; Maier, Lars S.; Conti, Marco; Wess, J.; El‐Armouche, Ali; Hasenfuß, Gerd; Nikolaev, Viacheslav O.

doi:10.1038/s41598-017-15632-x

Cited by 15 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Implantable ECG telemetry. Mice were subcutaneously implanted with telemeter transmitters (ETA-F10; Data Sciences International, MA, USA), and the electrode leads were subcutaneously secured in a lead II configuration as reported elsewhere 43 . Continuous ECG recordings in conscious mice were acquired for 3 weeks, and analysed using Ponemah software (version 6.41; Data Sciences International).…”

Section: Rna-seq Analysismentioning

confidence: 99%

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy

Eijgenraam

Boukens

Boogerd

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Phospholamban (PLN) plays a role in cardiomyocyte calcium handling as primary inhibitor of sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). The p.(Arg14del) pathogenic variant in the PLN gene results in a high risk of developing dilated or arrhythmogenic cardiomyopathy with heart failure. There is no established treatment other than standard heart failure therapy or heart transplantation. In this study, we generated a novel mouse model with the PLN-R14del pathogenic variant, performed detailed phenotyping, and tested the efficacy of established heart failure therapies eplerenone or metoprolol. Heterozygous PLN-R14del mice demonstrated increased susceptibility to ex vivo induced arrhythmias, and cardiomyopathy at 18 months of age, which was not accelerated by isoproterenol infusion. Homozygous PLN-R14del mice exhibited an accelerated phenotype including cardiac dilatation, contractile dysfunction, decreased ECG potentials, high susceptibility to ex vivo induced arrhythmias, myocardial fibrosis, PLN protein aggregation, and early mortality. Neither eplerenone nor metoprolol administration improved cardiac function or survival. In conclusion, our novel PLN-R14del mouse model exhibits most features of human disease. Administration of standard heart failure therapy did not rescue the phenotype, underscoring the need for better understanding of the pathophysiology of PLN-R14del-associated cardiomyopathy. This model provides a great opportunity to study the pathophysiology, and to screen for potential therapeutic treatments.

show abstract

Section: Rna-seq Analysismentioning

confidence: 99%

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy

Eijgenraam

Boukens

Boogerd

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Atropine is a mAChR antagonist [63,64] . Atropine blocks the inhibitory effect of AC, leading to tachyarrhythmias [64] .…”

Section: Atropha Belladonnamentioning

confidence: 99%

Pharmacological Basis of Similia Similibus Curantur and the Nature of Homeopathic Materia Medica

Lingeswaran¹,

Mohan

2023

Int J Ayu Pharm Res

View full text Add to dashboard Cite

Similia Similibus Curantur is also called the law of similars. That is, when a drug produces pathological/pathogenic symptoms in healthy individual means, the same drug can relieve similar kinds of symptoms in individuals with the disease. The biological, pharmacological and toxicological action of capsaicin alkaloids is a perfect example to explain the Similia Similibus Curantur principle. Most of the drugs in homoeopathic materia medica contain toxicological, pharmacological, drug-proving, and traditional use-related symptoms and indications. Abnormal sensations and symptoms of the disease are caused by the involvement of a specific receptor or molecular pathway and gene functions. These receptors or molecules may be stimulated or suppressed by environmental, natural or artificial agents. In such conditions, the administration of specific homoeopathic medicine having a similar kind of affinity towards the particular receptors or molecules involved in the disease process leads to modulation of such receptor or molecular pathways (e.g., desensitization, sensitization, inhibition). These kinds of actions cause the betterment of symptoms or curative effects. So “Similia similibus curanter” can be understood as a similar receptor or molecular pathway involved in both drug molecules biological/ pharmacological and toxicological action and disease pathogenesis". The selection of medicine is by comparing the similarity between the receptor or molecular pathway in disease pathogenesis and drug pathogenesis. To avoid unwanted aggravations or side effects while using mother tinctures or solutions, administer them less than their physiological dose. The theory of the pharmacological basis of Similia Similia Curantur creates a rational method to apply this Similia Principle. Based on this theory, there is a possibility of discovering Novel drugs in the future that acts and gives a cure in similia similibus curantur way.

show abstract

“…Jednym z zagrożeń jest bradykardia i spadek rzutu serca oraz skurcz oskrzeli, nadmierne wydzielanie śliny, śluzu a także wzrost wydzielania żołądkowego. Atropina jest jednym z leków antycholinergicznych, który blokuje hamujące działanie przywspółczulne i przyspiesza czynność serca [86]. Podczas jej stosowania obserwuje się spadek ryzyka bradykardii oraz ślinotoku, ale jednocześnie -jak wskazują badania -częstsze wzrosty ciśnienia tętniczego krwi.…”

Section: Stabilizacja Układu Krążeniaunclassified

Application of anesthetic premedication in palliative medicine

Prusator-Żędzian¹,

Jasiewicz²,

Kościuczuk³

et al. 2021

View full text Add to dashboard Cite

as well as gabapentinoids and painkillers, are recommended drugs. A wide range of other medications is used for the premedication of patients in palliative medicine. Giving up premedication before painful procedures and surgery in the group of palliative medicine patients is not recommended. The benefits of premedication in the form of anxiolytic and analgesic effects outweigh the potential side effects of premedication drugs.

show abstract

Atropine augments cardiac contractility by inhibiting cAMP-specific phosphodiesterase type 4

Cited by 15 publications

References 37 publications

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy

Pharmacological Basis of Similia Similibus Curantur and the Nature of Homeopathic Materia Medica

Application of anesthetic premedication in palliative medicine

Contact Info

Product

Resources

About